Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 602
- 试验地点
- 1
- 主要终点
- Number of medicine, surgery, obstetrics and odontology (MCO) stays per patient
研究概览
简要总结
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Number of medicine, surgery, obstetrics and odontology (MCO) stays per patient
时间窗: Up to 36 months
Number of outpatient visit (ACE) stays per patient
时间窗: Up to 36 months
Number of homecare (HAD) stays per patient
时间窗: Up to 36 months
Number of patients who died
时间窗: Up to 36 months
Cost of CAR-T on the supplementary list
时间窗: Up to 36 months
Cost of medicines on the supplementary list (excluding CAR-T)
时间窗: Up to 36 months
Hospitalisation cost
时间窗: Up to 36 months
Number of emergency room visits not followed by hospitalisation per patient
时间窗: Up to 36 months
Number of consultations per type of healthcare professional
时间窗: Up to 36 months
Number of aftercare and rehabilitation (SSR) stays per patient
时间窗: Up to 36 months
Cost of MCO hospitalisation
时间窗: Up to 36 months
Number of consultations per patient (all consultations combined)
时间窗: Up to 36 months
次要结局
未报告次要终点